Janssen Search
Search results
The IL-23 Pathway: Defining a New Paradigm in Immunology
The IL-23 Pathway: Defining a New Paradigm in Immunology The discovery of the IL-23 pathway and elucidation of its role in autoimmunity has led to a paradigm shift within the field of immunology. Decades ago, T cells were divided into CD4+ helper and CD8+ ...
Kevin Hamill
KEVIN HAMILL VICE PRESIDENT JANSSEN BUSINESS DEVELOPMENT IMMUNOLOGY Kevin Hamill is Vice President, Business Development for the Immunology Therapeutic Area (TA) at Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads all ...
See the Change, Be the Change
See the Change; Be the Change – Global Regulatory Affairs Colleagues Are Shaping the Future As Nelson Mandela said, “Education is the most powerful weapon which you can use to change the world.” Each September, I think about the millions of eager students ...
Sean Larkin, MBA
Sean Larkin, MBA is responsible for developing and executing the end-to-end strategy for the Disease Area Stronghold focused on inflammatory bowel disease. In this role, he leads all new product commercialization activities, portfolio evaluations, ...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
Jun 03, 2024 73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy 1 CHICAGO (June 3, 2024) – Johnson & Johnson ...
Our Recognition
Article Block Text: We are honored to receive awards and recognition for our work and community contributions around the world. Article Type: Explore We are honored to receive awards and recognition for our work and community contributions around the ...
JDRF partnership
Janssen Sets a Course to Intercept Type 1 Diabetes Together with JDRF As part of its disease interception strategy to halt progression of type 1 diabetes (T1D) before the disease manifests, the Disease Interception Accelerator (DIA) began a research ...
Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
Jun 05, 2023 United States More than 60 percent of patients achieved an overall response and 45.5 percent of patients achieved a complete response or better by nearly five months Additional data highlights strong efficacy with biweekly TECVAYLI ® dosing ...
Nauman Shah
NAUMAN SHAH GLOBAL HEAD JANSSEN BUSINESS DEVELOPMENT Nauman Shah is Global Head, Janssen Business Development. In this role, Nauman leads the Janssen Business Development organization in the identification, evaluation, execution, integration and ...
Simon Lovestone, B.SC., B.M., Ph.D.
SIMON LOVESTONE, B.SC., B.M., PH.D. GLOBAL HEAD OF DISCOVERY AND TRANSLATIONAL RESEARCH Simon Lovestone, B.SC., B.M., Ph.D., is Global Head of Discovery and Translational Research for Janssen Neuroscience, where he leads the global Johnson & Johnson ...